|
[1]Friedman SL.Hepatic stellate cells:protean, multifunctional, andenigmatic cells of the liver[J].Physiol Rev, 2008, 88 (1) :125-172.
|
|
[2]Kordes C, Sawitza I, Muller-Marbach A, et al.CD133+hepaticstellate cells are progenitor cells[J].Biochem Biophys Res Com-mun, 2007, 352 (2) :410-417.
|
|
[3]Zeisberg M, Yang C, Martino M, et al.Fibroblasts derive from hepato-cytes in liver fibrosis via epithelial to mesenchymal transition[J].J Bi-ol Chem, 2007, 282 (32) :23337-23347.
|
|
[4]Taura K, Miura K, Iwaisako K, et al.Hepatocytes do not undergoepithelial-mesenchymal transition in liver fibrosis in mice[J].Hepatology, 2010, 51 (3) :1027-1036.
|
|
[5]Choi SS, Diehl AM.Epithelial-to-mesenchymal transitions inthe liver[J].Hepatology, 2009, 50 (6) :2007-2013.
|
|
[6]Yoshiji H, Kuriyama S, Yoshii J, et al.Vascular endothelialgrowth factor and receptor interaction is a prerequisite for murinehepatic fibrogenesis[J].Gut, 2003, 52 (9) :1347-1354.
|
|
[7]Bockx I, Verdrengh K, Vander Elst I, et al.High-frequency va-gus nerve stimulation improves portal hypertension in cirrhotic rats[J].Gut, 2012, 61 (4) :604-612.
|
|
[8]Steib CJ, Gerbes AL, Bystron M, et al.Kupffer cell activation in nor-mal and fibrotic livers increases portal pressure via thromboxane A (2) [J].J Hepatol, 2007, 47 (2) :228-238.
|
|
[9]Holland-Fischer P, Gronbaek H, Sandahl TD, et al.Kupffer cellsare activated in cirrhotic portal hypertension and not normalised byTIPS[J].Gut, 2011, 60 (10) :1389-1393.
|
|
[10]Lebrec D, Sogni P, Vilgrain V.Evaluation of patients with portalhypertension[J].Baillieres Clin Gastroenterol, 1997, 11 (2) :221-241.
|
|
[11]Poynard T, Munteanu M, Deckmyn O, et al.Validation of liver fi-brosis biomarker (FibroTest) for assessing liver fibrosis progression:proof of concept and first application in a large population[J].JHepatol, 2012, 57 (3) :541-548.
|
|
[12]Thabut D, Imbert-Bismut F, Cazals-Hatem D, et al.Relation-ship between the Fibrotest and portal hypertension in patients withliver disease[J].Aliment Pharmacol Ther, 2007, 26 (3) :359-368.
|
|
[13]Ngo Y, Benhamou Y, Thibault V, et al.An accurate definition ofthe status of inactive hepatitis B virus carrier by a combination of bi-omarkers (FibroTest-ActiTest) and viral load[J].PLoS One, 2008, 3 (7) :e2573.
|
|
[14]Tsochatzis EA, Gurusamy KS, Ntaoula S, et al.Elastography forthe diagnosis of severity of fibrosis in chronic liver disease:a meta-analysis of diagnostic accuracy[J].J Hepatol, 2011, 54 (4) :650-659.
|
|
[15]Roulot D, Costes JL, Buyck JF, et al.Transient elastography as ascreening tool for liver fibrosis and cirrhosis in a community-basedpopulation aged over 45 years[J].Gut, 2011, 60 (7) :977-984.
|
|
[16]Vizzutti F, Arena U, Romanelli RG, et al.Liver stiffness measurementpredicts severe portal hypertension in patients with HCV-related cir-rhosis[J].Hepatology, 2007, 45 (5) :1290-1297.
|
|
[17]Ran HT, Ye XP, Zheng YY, et al.Spleen stiffness and splenopor-tal venous flow:assessment before and after transjugular intrahepaticportosystemic shunt placement[J].J Ultrasound Med, 2013, 32 (2) :221-228.
|
|
[18] Chinese Society of Hepatology and Chinese Society of Infectious Dis-eases, Chinese Medical Association.The Guideline of preventionand treatment for chronic hepatitis B (2010 version) [J].J ClinHepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学合肝病学分会, 感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.
|
|
[19]Mutimer DJ, Lok A.Management of HBV-and HCV-inducedend stage liver disease[J].Gut, 2012, 61 (Suppl 1) :i59-67.
|
|
[20]Yokohama S, Yoneda M, Haneda M, et al.Therapeutic efficacy ofan angiotensin II receptor antagonist in patients with nonalcoholicsteatohepatitis[J].Hepatology, 2004, 40 (5) :1222-1225.
|
|
[21]Abramovitch S, Dahan-Bachar L, Sharvit E, et al.Vitamin D in-hibits proliferation and profibrotic marker expression in hepatic stel-late cells and decreases thioacetamide-induced liver fibrosis in rats[J].Gut, 2011, 60 (12) :1728-1737.
|
|
[22]Tugues S, Fernandez-Varo G, Munoz-Luque J, et al.Antiangio-genic treatment with sunitinib ameliorates inflammatory infiltrate, fi-brosis, and portal pressure in cirrhotic rats[J].Hepatology, 2007, 46:1919-1926.
|
|
[23]Bari K, Garcia-Tsao G.Treatment of portal hypertension[J].World JGastroenterol, 2012, 18 (11) :1166-1175.
|
|
[24]Steib CJ, Hennenberg M, Beitinger F, et al.Amiloride reducesportal hypertension in rat liver cirrhosis[J].Gut, 2010, 59 (6) :827-836.
|
|
[25]Runyon BA.Management of adult patients with ascites due to cir-rhosis:an update[J].Hepatology, 2009, 49 (6) :2087-2107.
|
|
[26]Haussinger D, Schliess F.Pathogenetic mechanisms of hepatic en-cephalopathy[J].Gut, 2008, 57 (8) :1156-1165.
|
DownLoad: